Back to top
more

Spectrum Pharmaceuticals, Inc. (SPPI)

(Delayed Data from NSDQ)

$9.80 USD

9.80
798,350

+0.50 (5.38%)

Updated May 3, 2019 04:00 PM ET

After-Market: $9.81 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 60% and 27.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Spectrum Pharmaceuticals (SPPI) Reports Q4 Loss, Tops Revenue Estimates

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 33.33% and 5.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug

The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.

Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection

Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.

Liminal (LMNL) Ends Development of Lead Candidate, Stock Down

Based on results from an early-stage study, Liminal BioSciences (LMNL) decides to discontinue the development of its lead pipeline candidate, fezagepras.

Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M

Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.

Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study

Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.

Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals

Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.

Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug

Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.

    Best Momentum Stocks to Buy for July 13th

    JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.

    New Strong Buy Stocks for July 13th

    KMI, UFCS, GKOS, SPPI and BECN have been added to the Zacks Rank #1 (Strong Buy) List on July 13, 2022.

    Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns

    Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.

    Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales

    Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.

    Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

    Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.

    Down 55.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)

    The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study

    PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.

    Do Options Traders Know Something About Spectrum Pharmaceuticals (SPPI) Stock We Don't?

    Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

    Down 38% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)

    The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    Aditi Saraogi headshot

    Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options

    Investors need to pay close attention to for Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

    Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation

    The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.

    Spectrum Pharmaceuticals (SPPI) Reports Q3 Loss, Misses Revenue Estimates

    Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Spectrum Pharmaceuticals (SPPI) Jumps: Stock Rises 7%

    Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

    Implied Volatility Surging for Spectrum (SPPI) Stock Options

    Investors need to pay close attention to Spectrum (SPPI) stock based on the movements in the options market lately.